Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of QHRD107 combined with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia
CTR20232448Phase 2Active
- Sponsor
- Qianhong Biopharmaceutical
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QHRD107 in acute myeloid leukemia (AML), sponsored by Qianhong Biopharmaceutical. Started Aug 2023; status: active.
02
Drugs
QHRD107
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20232448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232448.